Pharmaceutical

Coherus offloads Humira biosimilar Yusimry for $40m

Hong Kong King-Friend Industrial has acquired worldwide rights to Yusimry, and its subsidiary, Meitheal, will market the therapy in the US.

Jun 30, 2024 - 04:00
Coherus offloads Humira biosimilar Yusimry for $40m
Hong Kong King-Friend Industrial has acquired worldwide rights to Yusimry, and its subsidiary, Meitheal, will market the therapy in the US.
Read the original article

Tags:

Previous Article

Amylyx ventures into metabolic diseases market with $35.1m deal

Next Article

Can routinely collected primary care data drive life sciences investment in the UK?

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Congress extends some pandemic preparedness programs, but not all

STAT+: Congress extends some pandemic preparedness prog...

Oct 2, 2023

American Cancer Society expands lung cancer screening guidelines for cigarette smokers

American Cancer Society expands lung cancer screening g...

Nov 1, 2023

STAT+: Neuralink can now study its brain implant in humans, but it’s still catching up to its peers

STAT+: Neuralink can now study its brain implant in hum...

May 27, 2023